PT  - JOURNAL ARTICLE
AU  - YUKI HIROSE
AU  - JUN SAKATA
AU  - TAKASHI KOBAYASHI
AU  - KOHEI MIURA
AU  - KIZUKI YUZA
AU  - MAE NAKANO
AU  - HIROSHI ICHIKAWA
AU  - MASAYUKI NAGAHASHI
AU  - YOSHIFUMI SHIMADA
AU  - HITOSHI KAMEYAMA
AU  - TOSHIFUMI WAKAI
TI  - NQO1 as a Marker of Chemosensitivity and Prognosis for Colorectal Liver Metastasis
AID  - 10.21873/anticanres.14916
DP  - 2021 Mar 01
TA  - Anticancer Research
PG  - 1563--1570
VI  - 41
IP  - 3
4099  - http://ar.iiarjournals.org/content/41/3/1563.short
4100  - http://ar.iiarjournals.org/content/41/3/1563.full
SO  - Anticancer Res2021 Mar 01; 41
AB  - Background/Aim: This study aimed to evaluate how NAD(P)H: quinone oxidoreductase-1 (NQO1) affects survival after hepatectomy in patients with colorectal liver metastasis (CRLM). Patients and Methods: A retrospective analysis was conducted of 88 consecutive patients who underwent hepatectomy for CRLM. Of the 88 patients, preoperative chemotherapy was administered to 30 patients. Immunohistochemistry of the resected specimens was conducted using monoclonal anti-NQO1 antibody. Results: NQO1-positive expression in tumor cells of CRLM was associated with worse overall survival (p=0.026) and was an independent adverse prognostic factor in multivariate analysis (hazard ratio=5.296, p=0.007). Among 30 patients who received preoperative chemotherapy, patients with loss of NQO1 expression in non-neoplastic epithelial cells of the bile ducts (NQO1 polymorphism: n=19) showed significantly better response to preoperative chemotherapy for CRLM (p=0.004). Conclusion: NQO1-positive expression in tumor cells of CRLM may be an adverse prognostic factor after hepatectomy for CRLM.